Medicine Man Technologies, Inc.

OTCPK:SHWZ Stock Report

Market Cap: US$1.6m

Medicine Man Technologies Valuation

Is SHWZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHWZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SHWZ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SHWZ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHWZ?

Key metric: As SHWZ is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SHWZ. This is calculated by dividing SHWZ's market cap by their current revenue.
What is SHWZ's PS Ratio?
PS Ratio0.009x
SalesUS$174.91m
Market CapUS$1.60m

Price to Sales Ratio vs Peers

How does SHWZ's PS Ratio compare to its peers?

The above table shows the PS ratio for SHWZ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
EMMA Emmaus Life Sciences
0.09xn/aUS$1.8m
SNES SenesTech
1.2x37.0%US$2.3m
EVFM Evofem Biosciences
0.05xn/aUS$906.9k
AKAN Akanda
0.8xn/aUS$2.1m
SHWZ Medicine Man Technologies
0.009x6.4%US$1.6m

Price-To-Sales vs Peers: SHWZ is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does SHWZ's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

69 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x8.3%
SHWZ Medicine Man Technologies
 0.009x6.4%US$1.60m
VTRS Viatris
0.7x-0.9%US$10.86b
OGN Organon
0.6x0.4%US$3.95b
SHWZ 0.0xIndustry Avg. 2.9xNo. of Companies69PS03.67.210.814.418+
69 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x17.0%
SHWZ Medicine Man Technologies
 0.009xn/aUS$1.60m
No more companies

Price-To-Sales vs Industry: SHWZ is good value based on its Price-To-Sales Ratio (0x) compared to the US Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is SHWZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHWZ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.009x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SHWZ's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SHWZ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.02
US$2.70
+13,412.5%
48.0%US$4.00US$1.41n/a2
Mar ’26US$0.0055
US$2.70
+49,036.4%
48.0%US$4.00US$1.41n/a2
Feb ’26US$0.02
US$2.64
+13,110.0%
40.0%US$4.00US$1.43n/a3
Jan ’26US$0.02
US$2.64
+13,110.0%
40.0%US$4.00US$1.43n/a3
Dec ’25US$0.10
US$2.66
+2,556.7%
39.1%US$4.00US$1.47n/a3
Nov ’25US$0.11
US$2.66
+2,315.2%
39.1%US$4.00US$1.47n/a3
Oct ’25US$0.14
US$2.65
+1,865.2%
39.3%US$4.00US$1.46n/a3
Sep ’25US$0.11
US$2.65
+2,311.8%
39.3%US$4.00US$1.46n/a3
Aug ’25US$0.20
US$2.65
+1,238.0%
39.6%US$4.00US$1.44n/a3
Jul ’25US$0.40
US$2.66
+564.1%
39.1%US$4.00US$1.47n/a3
Jun ’25US$0.46
US$2.66
+483.8%
39.1%US$4.00US$1.47n/a3
May ’25US$0.65
US$2.66
+309.1%
38.9%US$4.00US$1.48n/a3
Apr ’25US$0.77
US$2.66
+244.2%
38.9%US$4.00US$1.48n/a3
Mar ’25US$1.21
US$3.07
+154.6%
23.8%US$4.00US$2.21US$0.00553
Feb ’25US$1.18
US$3.06
+159.4%
24.3%US$4.00US$2.18US$0.023
Jan ’25US$0.61
US$3.06
+401.9%
24.3%US$4.00US$2.18US$0.023
Dec ’24US$0.55
US$3.06
+456.4%
24.3%US$4.00US$2.18US$0.103
Nov ’24US$0.60
US$3.08
+412.6%
23.6%US$4.00US$2.23US$0.113
Oct ’24US$0.79
US$3.08
+288.8%
23.6%US$4.00US$2.23US$0.143
Sep ’24US$0.83
US$3.08
+270.5%
23.6%US$4.00US$2.23US$0.113
Aug ’24US$0.88
US$3.08
+249.4%
23.6%US$4.00US$2.23US$0.203
Jul ’24US$1.08
US$3.08
+184.7%
23.6%US$4.00US$2.23US$0.403
Jun ’24US$0.98
US$3.08
+212.5%
23.6%US$4.00US$2.23US$0.463
May ’24US$1.12
US$3.07
+174.0%
23.9%US$4.00US$2.21US$0.653
Apr ’24US$1.13
US$2.93
+158.7%
23.2%US$4.00US$2.22US$0.774
Mar ’24US$1.27
US$2.94
+131.2%
22.9%US$4.00US$2.24US$1.214
Analyst Price Target
Consensus Narrative from 2 Analysts
US$2.70
Fair Value
99.3% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 10:38
End of Day Share Price 2025/03/14 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicine Man Technologies, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell StanleyBeacon Securities Limited
Jonathan DeCourceyBTIG
Joseph GomesNOBLE Capital Markets, Inc.